## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appli	cation of: Hyd	o-Juon Kim	Confirmation No.: 1247				
Serial No.	10/593,41	3	Group Art Unit: 1648				
Filed:	9/29/08		Examiner: Bo Peng				
	or: ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION						
Attorney D	Oocket No.: 02	220.00002					
Commissi P.O. Box	Sequence oner for Pater 1450 a, VA 22313-						
	SUBMISSION OF SEQUENCE LISTING/STATEMENT						
1.	1. This replies to the Notice to Comply issued January 29, 2009.						
	<u>X</u> A c	opy of the communicat	ion is enclosed.				
2.	I, Kenneth	I. Kohn, state the follo	owing:				
3.	Submitted	herewith is/are:					
	<u>X</u> A.	Sequence Listing(s) for sequence(s).	or the nucleotide and/or amino acid				
		Each sequence Listing	g is assigned a separate identifier.				
	_X B.	A copy of each Seque application in comput	nce Listing submitted for this er readable form.				
	C.	Preliminary Amendmenthe application.	ent inserting the Sequence Listing into				
	I hereby certify the United Stat		electronically filed with seabove date.				

Lenny Honet

# STATEMENT THAT SEQUENCE LISTING AND COMPUTER READABLE COPY ARE THE SAME

I hereby state that each computer readable form submitted in this application is the same as the paper copy of the Sequence Listing to which it is indicated to relate.

I hereby state that all papers accompanying this submission, or for which a request for transfer from Applicants' other application, introduce no new matter.

The Commissioner is authorized to charge any fee or credit any overpayment in connection with this communication to our Deposit Account No. 11-1449.

Respectfully submitted,

KOHN & ASSOCIATES, PLLC

Kenneth I. Kohn

Registration No. 30,955 Customer No.: 48924

Dated: 2/13/09

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 20231

APPLICATION NO. /CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10593413		KIM, HYO-JOON	0220.00002

**EXAMINER BO PENG** 

**ART UNIT PAPER** 1648 20090123

#### DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Web (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual - ePAVE)
- 2. Mailed to:

Mail Stop Sequence Commissioner for Patents P.O. Box 22313 1450 Alexandria, VA 22313 1450

3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:

U.S. Patent and Trademark Office

Mail Stop Sequence

Customer Window

Randolph Building

401 Dulaney Street

Alexandria, VA 22314

Any inquiry concerning this communication should be directed to Bo Peng at telephone number (571)272-5542. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can be reached on

/BO PENG/

Examiner, Art Unit: 1648

	Application No. 10/593,413	Applicant(s) Kim	
Notice to Comply	Examiner Bo Peng, Ph.D.	Art Unit 1648	

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).				
<ul> <li>2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</li> </ul>				
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
☐ 7. Other:				
Applicant Must Provide:  ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these requirements, please contact:				
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. PatentIn Software Program Support				
Technical Assistance703-287-0200 To Purchase PatentIn Software703-306-2600				
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY				